Drugs / Plasmin (Human)
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00418483 | Mar 2007 → Apr 2010 | arterial occlusion | Grifols Therapeutics LLC | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01014975 | Nov 2009 → Nov 2013 | ischemic stroke | Grifols Therapeutics LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Plasmin (Human) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00418483 ↗ |
| Modality | Protein / enzyme biologic | “Biological: Plasmin (Human) 25 mg” NCT00418483 ↗ |
| Route | Other | “Plasmin (Human) 25 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.” NCT00418483 ↗ |